Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 (COVID-19)
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, Exchange transfusion, Methylene blue
Eligibility Criteria
Inclusion Criteria:
- Adult patients are 18 years old or above.
- Inpatients diagnosed as severe COVID - 19 disease according to WHO criteria.
- CT chest with extensive lung disease (ground-glass and consolidative pulmonary opacities).
- O2 saturation less than 93% resting.
- Respiratory rate equal or more than 30 per minute.
Exclusion Criteria:
- Patients with pregnancy and lactation.
- Renal failure and heart failure.
- Contraindication for plasma or blood transfusion.
Sites / Locations
- Ain Shams UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Exchange transfusion
Methylene blue with plasma
Exchange transfusion and methylene blue with plasma
Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.